{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T14:31:48Z","timestamp":1772375508131,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL085561"],"award-info":[{"award-number":["R01-HL085561"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL097047"],"award-info":[{"award-number":["R01-HL097047"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.amjmed.2023.03.017","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:54:01Z","timestamp":1680519241000},"page":"677-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease"],"prefix":"10.1016","volume":"136","author":[{"given":"Samir","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos I.","family":"Kanonidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amiya A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesh K.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherinne","family":"Arundel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Faselis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis E.","family":"Kanonidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Allman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farooq H.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.amjmed.2023.03.017_bib0001","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2023.03.017_bib0002","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jchf.2019.02.009","article-title":"Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease","volume":"7","author":"Hein","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"10","key":"10.1016\/j.amjmed.2023.03.017_bib0003","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1046\/j.1532-5415.2002.50457.x","article-title":"Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications","volume":"50","author":"Ahmed","year":"2002","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"10.1016\/j.amjmed.2023.03.017_bib0004","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cardfail.2006.05.008","article-title":"Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis","volume":"12","author":"Ahmed","year":"2006","journal-title":"J Card Fail"},{"issue":"4","key":"10.1016\/j.amjmed.2023.03.017_bib0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjmed.2011.10.013","article-title":"Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease","volume":"125","author":"Ahmed","year":"2012","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2023.03.017_bib0006","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjmed.2012.06.031","article-title":"Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease","volume":"126","author":"Ahmed","year":"2013","journal-title":"Am J Med"},{"issue":"34","key":"10.1016\/j.amjmed.2023.03.017_bib0007","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/eurheartj\/ehv300","article-title":"Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues","volume":"36","author":"Dickstein","year":"2015","journal-title":"Eur Heart J"},{"issue":"34","key":"10.1016\/j.amjmed.2023.03.017_bib0008","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehv268","article-title":"Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study","volume":"36","author":"Edner","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.amjmed.2023.03.017_bib0009","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.amjmed.2023.03.017_bib0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jacc.2021.05.027","article-title":"Heart failure and chronic kidney disease patients: first it is necessary to act","volume":"78","author":"Rossignol","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.03.017_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2004.03.004","article-title":"Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design","volume":"148","author":"Fonarow","year":"2004","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.amjmed.2023.03.017_bib0012","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.03.017_bib0013","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ijcard.2011.10.089","article-title":"Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data","volume":"166","author":"Zhang","year":"2013","journal-title":"Int J Cardiol"},{"issue":"24","key":"10.1016\/j.amjmed.2023.03.017_bib0014","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.jacc.2019.04.022","article-title":"Systolic blood pressure and outcomes in patients with heart failure with reduced ejection fraction","volume":"73","author":"Arundel","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2023.03.017_bib0015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.amjmed.2021.11.012","article-title":"Initiation of anti-hypertensive drugs and outcomes in patients with heart failure with reduced ejection fraction","volume":"135","author":"Lam","year":"2022","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2023.03.017_bib0016","first-page":"135","article-title":"Removal of race from estimates of kidney function: first, do no harm","volume":"325","author":"Norris","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.amjmed.2023.03.017_bib0017","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.amjmed.2023.03.017_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000328905","article-title":"Relationship between stage of kidney disease and incident heart failure in older adults","volume":"34","author":"Bowling","year":"2011","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.03.017_bib0019","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ndt\/gfn445","article-title":"Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study","volume":"24","author":"Campbell","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.amjmed.2023.03.017_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.amjmed.2023.03.017_bib0021","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity score to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"issue":"1","key":"10.1016\/j.amjmed.2023.03.017_bib0022","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCOUTCOMES.108.790634","article-title":"Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review","volume":"1","author":"Austin","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"10.1016\/j.amjmed.2023.03.017_bib0023","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.amjmed.2023.03.017_bib0024","first-page":"105","article-title":"Sensitivity to hidden bias","volume":"1","author":"Rosenbaum","year":"2002"},{"issue":"5","key":"10.1016\/j.amjmed.2023.03.017_bib0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2023.03.017_bib0026","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial","volume":"167","author":"Bowling","year":"2013","journal-title":"Int J Cardiol"},{"issue":"9386","key":"10.1016\/j.amjmed.2023.03.017_bib0027","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.amjmed.2023.03.017_bib0028","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.amjmed.2023.03.017_bib0029","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.amjmed.2023.03.017_bib0030","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2023.03.017_bib0031","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2023.03.017_bib0032","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0272-6386(96)90158-4","article-title":"Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial","volume":"27","author":"Ihle","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"9069","key":"10.1016\/j.amjmed.2023.03.017_bib0033","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.amjmed.2023.03.017_bib0034","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"23","key":"10.1016\/j.amjmed.2023.03.017_bib0035","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.amjmed.2023.03.017_bib0036","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.amjmed.2023.03.017_bib0037","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1046\/j.1523-1755.2003.00273.x","article-title":"Role of excess volume in the pathophysiology of hypertension in chronic kidney disease","volume":"64","author":"Vasavada","year":"2003","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.amjmed.2023.03.017_bib0038","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacc.2020.06.022","article-title":"Loop diuretic prescription and 30-day outcomes in older patients with heart failure","volume":"76","author":"Faselis","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2023.03.017_bib0039","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjmed.2020.11.019","article-title":"Loop diuretic prescription and long-term outcomes in heart failure: association modification by congestion","volume":"134","author":"Faselis","year":"2021","journal-title":"Am J Med"},{"issue":"9454","key":"10.1016\/j.amjmed.2023.03.017_bib0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","article-title":"Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.amjmed.2023.03.017_bib0041","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","article-title":"Angiotensin-converting enzyme inhibitors","volume":"97","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2023.03.017_bib0042","unstructured":"Ahmed A, Fonarow GC. The prevalent-user bias in observational studies and the importance of new-user design [letter to the editor]. Eur Heart J. 2019;40(40):3341. Available at: https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehz395\/5520008#usercomments. Accessed February 19, 2020."},{"issue":"5","key":"10.1016\/j.amjmed.2023.03.017_bib0043","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.amjmed.2017.11.011","article-title":"Effect of patiromer on hyperkalemia recurrence in older chronic kidney disease patients taking RAAS inhibitors","volume":"131","author":"Weir","year":"2018","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2023.03.017_bib0044","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.amjmed.2023.03.017_bib0045","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ehjcvp\/pvab033","article-title":"Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?","volume":"7","author":"Ameri","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.amjmed.2023.03.017_bib0046","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives","volume":"3","author":"Pitt","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"10.1016\/j.amjmed.2023.03.017_bib0047","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ejhf.937","article-title":"Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial","volume":"20","author":"Lam","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.amjmed.2023.03.017_bib0048","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.amjmed.2019.06.053","article-title":"Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD treatment trial","volume":"133","author":"Lam","year":"2020","journal-title":"Am J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293432300205X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293432300205X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:30:20Z","timestamp":1762079420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293432300205X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S000293432300205X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.03.017","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2023.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}